Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 20, 2025, the fund's latest net value is 1.5473 yuan, reflecting a growth of 2.76% [1] - The fund's one-month return is 5.29%, three-month return is 0.92%, and year-to-date return is 2.57%, with respective rankings of 3149 out of 4647, 1587 out of 4590, and 3094 out of 4546 [1] Group 2 - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

湖南启元律师事务所 关于爱尔眼科医院集团股份有限公司 2024年年度股东大会的 二零二五年五月二十日 法律意见书 致：爱尔眼科医院集团股份有限公司 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《爱 尔眼科医院集团股份有限公司章程》（以下简称"《公司章程》"）的有关规定 出具本法律意见书。 为出具本法律意见书，本所律师声明如下： （一）本所律师出具本法律意见书是基于公司已承诺所有提供给本所律师的 文件的正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠， 无隐瞒、虚假或重大遗漏之处。 （二）本所律师遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对 本法律意见书出具日以前已经发生或者存在的事实进行了充分的核查验证，保证 本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏。 （三）本所律师未授权任何单位或个人对本法律意见书作任何解释或说明。 为发表本法律意见，本所律师依法查验了 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-040 爱尔眼科医院集团股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 中小股东出席的总体情况： 通过网络投票的中小股东 1,989 人，代表股份 509,141,065 股，占公司有表 决权股份总数的 5.4772%。 其中：通过现场投票的股东 24 人，代表股份 4,976,884,056 股，占公司有表 决权股份总数的 53.5399％。 通过网络投票的股东 1,989 人，代表股份 509,141,065 股，占公司有表决权 股份总数的 5.4772%。 通过现场和网络投票的中小股东 2,010 人，代表股份 516,894,649 股，占公 司有表决权股份总数的 5.5606%。 爱尔眼科医院集团股份有限公司（以下简称"公司"）2024 年年度股东大 会采用现场表决与网络投票相结合的方式召开。其中，通过深圳证券交易所交 ...

2025.05. 20 本文字数：2818，阅读时长大约4分钟 作者 | 第一财经 孙梦凡 2025年以来，商办市场频现亿级大宗交易。 记者梳理发现，近期北京、上海、深圳等一线城市，均出现亿级大宗资产交易的案例，进场布局的买 家有科技行业的"新贵"，有地方国资企业，还有医疗领域的细分赛道"龙头"。 据克而瑞物管监测数据，截至2025年4月末，中国内地32城大宗物业挂牌总价约为3.49万亿元，环 比增加3.9%，同比增加84%，全国大宗资产项目挂牌量持续上升。那些"抄底"的企业或为经营自 用，或为布局核心城市资产，以对冲地方市场波动风险。 卖掉几个"小目标" 近日，北京市昌平区硅谷SOHO-2号楼项目成功出让，产权对价为人民币2.15亿元，单价每平方米 9880元，建筑面积21759平方米，买家为上海新黄浦实业集团股份有限公司。 该资产位于北京市昌平区中兴路21号院，原业主为北京博兴众业房地产开发有限公司。北京博兴众 业成立于2015年8月19日，主要经营范围包括房地产开发、销售商品房等。 早在2017年时，博兴众业便开发了硅谷SOHO-2号楼写字楼，该项目共17层，内部划分为415套 房，配备3部电梯，主力户 ...

爱尔眼科董事长陈邦：公司近期暂无港股上市打算 智通财经5月20日电，爱尔眼科董事长陈邦在今日举行的公司2024年度股东大会上，回答投资者"是否考 虑港股上市"的提问时表示，公司近期暂时没有这个打算。他说，"（港股）上市目的主要是筹集资金， 爱尔现在筹资能力很强，现金流也非常不错，银行放贷利息也低，因此近期没有这个打算。关键是看企 业的发展，有特别好的标的，资金能力又不够的话，那可能才会考虑。"（智通财经记者 李拥军） ...

Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology industry, suggesting it is at a turning point for profit improvement and has high allocation value [3][4]. Core Insights - The pharmaceutical sector is showing signs of recovery after three years of declining profitability, with a notable increase in net profit margin by 0.3% in Q1 2025 compared to the previous year [3][5]. - Key sub-sectors such as CXO, innovative drugs, biological products, private hospitals, and medical consumables have demonstrated strong performance in Q1 2025, with several leading companies exceeding expectations [3][4]. - The report recommends focusing on sub-sectors and companies with clear upward trends in performance, including innovative drugs and CXO services [3][4]. Overall Performance of the Sector - In 2024, 473 A-share pharmaceutical companies achieved total revenue of 24,588 billion yuan, a year-on-year decrease of 0.9%, and a net profit of 1,412 billion yuan, down 12.1% [3][5]. - For Q1 2025, the sector reported revenue of 6,104 billion yuan, a decline of 4.2% year-on-year, with net profit at 487 billion yuan, down 8.7% [3][5]. Sub-sector Performance - The CXO sector has shown a turnaround since Q4 2024, with Q1 2025 revenue of 225 billion yuan, reflecting an 11.6% year-on-year increase, and net profit of 50 billion yuan, up 72.8% [3][23]. - The innovative drug sector continues to grow rapidly, with leading companies like Heng Rui Medicine and Bai Jie Shen Zhou performing above expectations [3][18]. - The hospital sector is beginning to show signs of recovery, with Q1 2025 revenue of 144 billion yuan, a year-on-year increase of 4.9%, and net profit of 11 billion yuan, up 19.2% [3][28]. Investment Analysis - The report emphasizes the importance of investing in sectors and companies that are showing clear signs of upward trends, particularly in innovative drugs and CXO services [3][4]. - Specific companies recommended for investment include Heng Rui Medicine, Bai Jie Shen Zhou, and Wu Xi AppTec in the innovative drug and CXO sectors [3][4].

Core Viewpoint - Aier Eye Hospital (300015) and a research team from Nankai University have achieved a significant breakthrough in treating dry eye syndrome related to Sjögren's syndrome through the development of a "ROS-responsive microneedle patch" [1] Group 1 - The research findings were published in the international academic journal "Advanced Science" [1] - The paper was selected as the cover article for Volume 12, Issue 16, scheduled for publication on April 24, 2025, due to its innovation and academic value [1] - This breakthrough offers new treatment hope for patients suffering from dry eye syndrome related to Sjögren's syndrome (SSDE) [1]

5月15日，经济观察报获悉，南通爱尔眼科（300015）医院党支部书记、CEO于文娟被南通市崇川区纪 委给与党纪处分，同时，南通市崇川区政协撤销了于文娟的政协委员身份。 艾芬多次在社交平台质疑爱尔眼科的诊疗及管理问题，相关内容不仅关涉自身，也涉及其他曾在爱尔眼 科就诊的患者。 同时，艾芬亦对爱尔眼科员工提起过诉讼。艾芬曾起诉爱尔眼科职工段赛民、刘语菲、刘峰等侵犯名誉 权，2025年4月，武汉市江汉区人民法院一审判决艾芬胜诉。在该一审判决前后，艾芬的微博账号"急诊 向日葵艾芬"被封。 经济观察报注意到，《举报信》提到，南通市多名公职人员曾接受于文娟宴请。南通爱尔眼科医院一些 内部员工给艾芬提供了相应证据，包括南通爱尔眼科多份招待明细表，其中一些招待明细表的招待原因 标明为"业务拜访""业务拓展"。 南通爱尔眼科医院是爱尔眼科（300015.SZ）旗下医院。爱尔眼科成立于2003年，是中国眼科龙头，截 至2024年底，爱尔眼科在全球范围内共有974家品牌医院、眼科中心及诊所，其中811家在中国内地。此 前，爱尔眼科董事长陈邦曾于2022年初发内部信，称将全面拥抱社会监督。 艾芬曾在抗击新冠疫情中作出积极贡献，民间 ...

资金面上看，两市主力资金全天净流出538.30亿元，今日有5个行业主力资金净流入，医药生物行业主 力资金净流入规模居首，该行业今日下跌0.12%，全天净流入资金7.35亿元，其次是美容护理行业，日 涨幅为3.68%，净流入资金为3.86亿元。 医药生物行业资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002551 | 尚荣医疗 | -3.87 | 38.08 | -10593.02 | | 300015 | 爱尔眼科 | -1.91 | 0.57 | -7773.29 | | 603108 | 润达医疗 | -4.62 | 2.96 | -7658.97 | | 603883 | 老百姓 | -3.34 | 3.04 | -5645.74 | | 300760 | 迈瑞医疗 | -1.43 | 0.36 | -4751.79 | | 000623 | 吉林敖东 | -1.66 | 1.05 | -4283.38 | | 688166 | 博瑞医药 | -1.37 | 1.30 | - ...